Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter

Clinical Cancer Research

Volumn 12, Issue 6, 2006, Pages 1868-1875

  Hasegawa, Kosei ^a   Pham, Linh ^a   O'Connor, Michael K ^a   Federspiel, Mark J ^a   Russell, Stephen J ^a   Peng, Kah Whye ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARCINOEMBRYONIC ANTIGEN; PROBIOTIC AGENT; SODIUM IODIDE SYMPORTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MEASLES VIRUS; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; SCINTILLATION CAMERA; VIRAL GENETICS; VIRUS EXPRESSION; VIRUS INFECTION; XENOGRAFT;

ANIMALS; CARCINOEMBRYONIC ANTIGEN; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; FEMALE; HUMANS; IODINE RADIOISOTOPES; KINETICS; MEASLES VIRUS; MICE; MICE, NUDE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; OVARIAN NEOPLASMS; RECOMBINANT FUSION PROTEINS; SYMPORTERS; VERO CELLS; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33645663329     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1803     Document Type: Article

References (33)

1. Russell SJ. Replicating vectors for cancer therapy: a question of strategy. Semin Cancer Biol 1994;5:437-43.
2. Kim D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat Med 2001;7:781-7.
3. Vasey PA, Shulman LN, Campos S, et al. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dI1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol 2002;20:1562-9.
4. Nemunaitis J, Cunningham C, Buchanan A, et al. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther 2001;8:746-59.
5. Heise C, Ganly I, Kim YT, et al. Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status. Gene Ther 2000;7:1925-9.
6. Hirasawa K, Nishikawa SG, Norman KL, et al. Oncolytic reovirus against ovarian and colon cancer. Cancer Res 2002;62:1696-701.
7. Nakamori M, Fu X, Meng F, et al. Effective therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane fusion mechanisms. Clin Cancer Res 2003;9:2727-33.
8. Unno Y, Shino Y, Kondo F, et al. Oncolytic viral therapy for cervical and ovarian cancer cells by Sindbis virus AR339 strain. Clin Cancer Res 2005;11:4553-60.
9. Shafren DR, Sylvester D, Johansson ES, Campbell IG, Barry RD. Oncolysis of human ovarian cancers by echovirus type 1. Int J Cancer 2005;115:320-8.
10. Lam JT, Kanerva A, Bauerschmitz GJ, et al. Interpatient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapy. J Gene Med 2004;6:1333-42.
11. Myers R, Greiner S, Harvey M, et al. Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer. Cancer Gene Ther 2005;12:593-9.
12. Dingli D, Peng KW, Harvey ME, et al. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 2004;103:1641-6.
13. Peng KW, Ahmann GJ, Pham L, et al. Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood 2001;98:2002-7.
14. Peng KW, TenEyck CJ, Galanis E, et al. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res 2002;62:4656-62.
15. Phuong LK, Allen C, Peng KW, et al. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res 2003;63:2462-9.
16. Grote D, Russell SJ, Cornu TI, et al. Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood 2001;97:3746-54.
17. Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol 2003;40:109-23.
18. Bjorge L, Hakulinen J, Wahlstrom T, Matre R, Meri S. Complement- regulatory proteins in ovarian malignancies. Int J Cancer 1997;70:14-25.
19. Anderson BD, Nakamura T, Russell SJ, Peng KW. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res 2004;64:4919-26.
20. Gambhir SS, Herschman HR, Cherry SR, et al. Imaging transgene expression with radionuclide imaging technologies. Neoplasia 2000;2:118-38.
21. Herschman HR. Molecular imaging: looking at problems, seeing solutions. Science 2003;302:605-8.
22. Zinn KR, Chaudhuri TR. The type 2 human somatostatin receptor as a platform for reporter gene imaging. Eur J Nucl Med Mol Imaging 2002;29:388-99.
23. Dingli D, Russell SJ, Morris JC III. In vivo imaging and tumor therapy with the sodium iodide symporter. J Cell Biochem 2003;90:1079-86.
24. Liang Q, Gotts J, Satyamurthy N, et al. Noninvasive, repetitive, quantitative measurement of gene expression from a bicistronic message by positron emission tomography, following gene transfer with adenovirus. Mol Ther 2002;6:73-82.
25. Peng KW, Facteau S, Wegman T, O'Kane DRussell SJ. Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat Med 2002;8:527-31.
26. Kanerva A, Zinn KR, Peng KW, et al. Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus. Gene Ther 2005;12:87-94.
27. Boland A, Ricard M, Opolon P, et al. Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy. Cancer Res 2000;60:3484-92.
28. Gaut AW, Niu G, Krager KJ, et al. Genetically targeted radiotherapy of head and neck squamous cell carcinoma using the sodium-iodide symporter (NIS). Head Neck 2004;26:265-71.
29. Dingli D, Peng KW, Harvey ME, et al. Interaction of measles virus vectors with Auger electron emitting radioisotopes. Biochem Biophys Res Commun 2005;337:22-9.
30. Dadachova E, Carrasco N. The Na/I symporter (NIS): imaging and therapeutic applications. Semin Nucl Med 2004;34:23-31.
31. Dwyer RM, Bergert ER, O'Connor MK, Gendler SJ, Morris JC. In vivo radioiodide imaging and treatment of breast cancer xenografts after MUC1-driven expression of the sodium iodide symporter. Clin Cancer Res 2005;11:1483-9.
32. Cattaneo R, Rebmann G, Schmid A, et al. Altered transcription of a defective measles virus genome derived from a diseased human brain. EMBO J 1987;6:681-8.
33. Wodarz D. Gene therapy for killing p53-negative cancer cells: use of replicating versus nonreplicating agents. Hum Gene Ther 2003;14:153-9.